GlassScriptPhysician profile
Sara S Karowadia
NPI 1861123770
$2,567.93
in general payments reported to CMS, 2019-2025
26 companies · $2,129 in 2025
The $2,129 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $333 · 2024: $106 · 2025: $2,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $352.84 | 2023-2025 | Dupixent |
| Abbvie INC. | $322.87 | 2023-2025 | |
| Incyte Corporation | $316.09 | 2025 | Opzelura, Opzelura |
| Genzyme Corporation | $296.36 | 2023-2025 | |
| Janssen Biotech, INC. | $212.98 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $156.76 | 2025 | |
| Journey Medical Corporation | $123.69 | 2025 | |
| Galderma Laboratories, L.P. | $105.73 | 2025 | Nemluvio, Aklief, Dysport |
| Mayne Pharma Commercial LLC | $100.19 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.92 | 2023 | Cuvitru, Takhzyro |
| Ucb, INC. | $76.35 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $46.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $46.60 | 2023 | Fasenra |
| Antares Pharma, INC. | $44.24 | 2024 | Xyosted |
| Sumitomo Pharma America, INC. | $36.50 | 2024 | Gemtesa, Orgovyx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $36.17 | 2025 | |
| Organon LLC | $34.52 | 2025 | Vtama |
| Leo Pharma INC. | $30.08 | 2025 | Anzupgo |
| Bayer Healthcare Pharmaceuticals INC. | $25.11 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.03 | 2025 | Cabtreo |
| Pfizer INC. | $19.63 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.96 | 2025 | Sotyktu |
| Amgen INC. | $15.86 | 2025 | Otezla |
| Botanix Sb INC | $15.54 | 2025 | Sofdra |
| Lilly USA, LLC | $14.97 | 2025 | Ebglyss |
| Kaleo, INC. | $13.96 | 2023 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Karowadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.